News AZ grabs licence as Ionis NASH drug heads to the clinic Could antisense drug be a fatty liver disease blockbuster?
News AZ signs kidney drug deal with Ionis for up to $330m Deal is result of six-year collaboration with AZ
News Roche takes on development of potential Huntington’s breakth... Ionis has completed its licensing agreement with Roche for IONIS-HTTRx, a drug which could be a breakthrough in treating Huntington’s disease.
News Alnylam soars after drug success, paving way for RNAi era Shares in US biotech Alnylam have soared after a late-stage study of its RNA interference drug patisaran met its primary endpoint.
News Ionis to file rare disease drug after GSK declines option Firm turns down options for inotersen and IONIS-FB-LRX.
News Novartis, BMS, Janssen unveil R&D deals Companies announce eye-catching R&D plans ahead of conference.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
